Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy

Pei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, Meng-Hsuan Hsieh, Hsing-Tao Kuo, Chao-Hung Hung, Kuo-Chih Tseng, Hsueh-Chou Lai, Cheng-Yuan Peng, Jing-Houng Wang, Jyh-Jou Chen, Pei-Lun Lee, Rong-Nan Chien, Chi-Chieh Yang, Gin-Ho Lo, Jia-Horng Kao, Chun-Jen Liu, Chen-Hua Liu, Sheng-Lei Yan, Chun-Yen Lin, Wei-Wen Su, Cheng-Hsin Chu, Chih-Jen Chen, Shui-Yi Tung, Chi‐Ming Tai, Chih-Wen Lin, Ching-Chu Lo, Pin-Nan Cheng, Yen-Cheng Chiu, Chia-Chi Wang, Jin-Shiung Cheng, Wei-Lun Tsai, Han-Chieh Lin, Yi-Hsiang Huang, Chi-Yi Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chung, Ming-Jong Bair, Ming-Lung Yu

Clin Mol Hepatol. 2024;30(3):468-486. Published online April 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0038

View: 1302 Download: 115

Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis

Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George

Clin Mol Hepatol. 2024;30(3):436-448. Published online April 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0109

View: 1365 Download: 164 Crossref: 1

Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma

Chun-Ting Ho, Elise Chia-Hui Tan, Pei-Chang Lee, Chi-Jen Chu, Yi-Hsiang Huang, Teh-Ia Huo, Yu-Hui Su, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su

Clin Mol Hepatol. 2024;30(3):406-420. Published online April 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0103

View: 1138 Download: 104

Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma

Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim

Clin Mol Hepatol. 2024;30(3):360-374. Published online March 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0042

View: 1596 Download: 196 Crossref: 1

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study

Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim

Clin Mol Hepatol. 2024;30(3):345-359. Published online March 12, 2024

DOI: https://doi.org/10.3350/cmh.2023.0553

View: 1541 Download: 226

Letter to the Editor

Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD

Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):263-265. Published online January 18, 2024

DOI: https://doi.org/10.3350/cmh.2023.0557

View: 2092 Download: 122 Web of Science: 3 Crossref: 5

Editorial

Steatotic liver disease: Know your enemies

Lung-Yi Mak

Clin Mol Hepatol. 2024;30(2):171-173. Published online February 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0078

View: 1889 Download: 70 Web of Science: 1 Crossref: 1

Exploring the prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma

Ji Eun Han, Hyo Jung Cho

Clin Mol Hepatol. 2024;30(2):160-163. Published online February 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0141

View: 1899 Download: 49

Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization

Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang

Clin Mol Hepatol. 2024;30(2):150-153. Published online February 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0116

View: 2496 Download: 71 Web of Science: 1 Crossref: 1

Letter to the Editor

Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Hinpetch Daungsupawong, Viroj Wiwanitkit

Clin Mol Hepatol. 2024;30(1):111-112. Published online October 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0394

View: 1579 Download: 52

Review

Recent advances in the management of hepatocellular carcinoma

Kamya Sankar, Jun Gong, Arsen Osipov, Steven A. Miles, Kambiz Kosari, Nicholas N. Nissen, Andrew E. Hendifar, Ekaterina K. Koltsova, Ju Dong Yang

Clin Mol Hepatol. 2024;30(1):1-15. Published online July 21, 2023

DOI: https://doi.org/10.3350/cmh.2023.0125

View: 6011 Download: 303 Web of Science: 7 Crossref: 8

Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(Suppl):S220-S227. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0360

View: 3666 Download: 134 Web of Science: 3 Crossref: 4

Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease

Karim Seif El Dahan, Darine Daher, Amit G. Singal

Clin Mol Hepatol. 2023;29(Suppl):S207-S219. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0247

View: 7524 Download: 165 Web of Science: 6 Crossref: 11

Original Article

Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection

Jeongin Yoo, Heejin Cho, Dong Ho Lee, Eun Ju Cho, Ijin Joo, Sun Kyung Jeon

Clin Mol Hepatol. 2023;29(4):1029-1042. Published online August 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0190

View: 2774 Download: 123 Web of Science: 1

Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis

Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim

Clin Mol Hepatol. 2023;29(4):1013-1028. Published online July 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0131

View: 3418 Download: 142 Web of Science: 2 Crossref: 3

Editorial

Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?

Hyo-Cheol Kim

Clin Mol Hepatol. 2023;29(4):984-986. Published online August 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0275

View: 1628 Download: 41

Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy

Sang Min Yoon

Clin Mol Hepatol. 2023;29(4):977-979. Published online August 31, 2023

DOI: https://doi.org/10.3350/cmh.2023.0336

View: 1477 Download: 41

Review

Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma

Sung Uk Lee, Tae Hyun Kim

Clin Mol Hepatol. 2023;29(4):958-968. Published online August 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0274

View: 2399 Download: 86 Web of Science: 2 Crossref: 2

Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma

Hwa Kyung Byun, Changhwan Kim, Jinsil Seong

Clin Mol Hepatol. 2023;29(4):945-957. Published online August 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0217

View: 2459 Download: 90 Web of Science: 3 Crossref: 3

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment

Landon L. Chan, Stephen L. Chan

Clin Mol Hepatol. 2023;29(4):909-923. Published online May 25, 2023

DOI: https://doi.org/10.3350/cmh.2023.0114

View: 2866 Download: 243 Web of Science: 5 Crossref: 7

Letter to the Editor

Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Amnuay Kleebayoon, Viroj Wiwanitkit

Clin Mol Hepatol. 2023;29(3):815-816. Published online May 24, 2023

DOI: https://doi.org/10.3350/cmh.2023.0170

View: 2054 Download: 57 Web of Science: 2 Crossref: 1

Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Hassam Ali

Clin Mol Hepatol. 2023;29(3):813-814. Published online May 19, 2023

DOI: https://doi.org/10.3350/cmh.2023.0120

View: 2129 Download: 67 Web of Science: 1

Original Article

Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis

Moon Haeng Hur, Yuri Cho, Do Young Kim, Jae Seung Lee, Gyoung Min Kim, Hyo-Cheol Kim, Dong Hyun Sinn, Dongho Hyun, Han Ah Lee, Yeon Seok Seo, In Joon Lee, Joong-Won Park, Yoon Jun Kim

Clin Mol Hepatol. 2023;29(3):763-778. Published online May 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0076

View: 3221 Download: 192 Web of Science: 2 Crossref: 3

Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients

Xiaoning Wu, Xiaoqian Xu, Jialing Zhou, Yameng Sun, Huiguo Ding, Wen Xie, Guofeng Chen, Anlin Ma, HongXin Piao, Bingqiong Wang, Shuyan Chen, Tongtong Meng, Xiaojuan Ou, Hwai-I Yang, Jidong Jia, Yuanyuan Kong, Hong You

Clin Mol Hepatol. 2023;29(3):747-762. Published online May 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0121

View: 2643 Download: 138 Crossref: 1

Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging

Yoon Jung Hwang, Jae Seok Bae, Youngeun Lee, Bo Yun Hur, Dong Ho Lee, Haeryoung Kim

Clin Mol Hepatol. 2023;29(3):733-746. Published online May 8, 2023

DOI: https://doi.org/10.3350/cmh.2023.0034

View: 3264 Download: 175 Web of Science: 4 Crossref: 4

Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis

Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vincent Wai-Sun Wong, Ming-Whei Yu, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(3):705-720. Published online May 8, 2023

DOI: https://doi.org/10.3350/cmh.2023.0004

View: 4254 Download: 226 Web of Science: 13 Crossref: 18

Review

Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection

Chih-Lin Lin, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(3):605-622. Published online February 15, 2023

DOI: https://doi.org/10.3350/cmh.2022.0342

View: 4535 Download: 300 Web of Science: 9 Crossref: 14

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity

Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2023;29(3):593-604. Published online February 13, 2023

DOI: https://doi.org/10.3350/cmh.2022.0391

View: 4116 Download: 335 Web of Science: 12 Crossref: 9

Guideline

Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association

Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim

Clin Mol Hepatol. 2023;29(3):521-541. Published online July 1, 2023

DOI: https://doi.org/10.3350/cmh.2023.0202

View: 3252 Download: 206 Web of Science: 7 Crossref: 7

Snapshot

Systemic therapy in advanced hepatocellular carcinoma

Joseph C. Ahn, Nguyen H. Tran, Ju Dong Yang

Clin Mol Hepatol. 2023;29(2):516-519. Published online February 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0051

View: 3847 Download: 164 Web of Science: 4 Crossref: 4

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Viewed By 5505	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5409	MAFLD: How is it different from NAFLD?
Viewed By 5220	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5098	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4732	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search